217 related articles for article (PubMed ID: 24113750)
1. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35.
MacKenzie AE; Caltabiano G; Kent TC; Jenkins L; McCallum JE; Hudson BD; Nicklin SA; Fawcett L; Markwick R; Charlton SJ; Milligan G
Mol Pharmacol; 2014 Jan; 85(1):91-104. PubMed ID: 24113750
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel GPR35 agonist with high and equipotent species potency for oral treatment of IBD.
Song Z; Lu D; Sun J; Ye Y; Fang J; Wang K; Guo S; Zhang Q; He X; Xie X; Shen J
Bioorg Med Chem; 2023 Dec; 96():117511. PubMed ID: 37976806
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of lodoxamide on hepatic steatosis through GPR35.
Nam SY; Park SJ; Im DS
Cell Signal; 2019 Jan; 53():190-200. PubMed ID: 30304698
[TBL] [Abstract][Full Text] [Related]
4. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action.
Jenkins L; Harries N; Lappin JE; MacKenzie AE; Neetoo-Isseljee Z; Southern C; McIver EG; Nicklin SA; Taylor DL; Milligan G
J Pharmacol Exp Ther; 2012 Dec; 343(3):683-95. PubMed ID: 22967846
[TBL] [Abstract][Full Text] [Related]
5. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium.
Yang Y; Lu JY; Wu X; Summer S; Whoriskey J; Saris C; Reagan JD
Pharmacology; 2010; 86(1):1-5. PubMed ID: 20559017
[TBL] [Abstract][Full Text] [Related]
6. GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?
Park SJ; Lee SJ; Nam SY; Im DS
Br J Pharmacol; 2018 Jan; 175(1):154-161. PubMed ID: 29068046
[TBL] [Abstract][Full Text] [Related]
7. Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.
Jenkins L; Alvarez-Curto E; Campbell K; de Munnik S; Canals M; Schlyer S; Milligan G
Br J Pharmacol; 2011 Feb; 162(3):733-48. PubMed ID: 20958291
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Mast Cell Activation by GPR35: GPR35 Is a Primary Target of Disodium Cromoglycate.
Oka M; Akaki S; Ohno O; Terasaki M; Hamaoka-Tamura Y; Saito M; Kato S; Inoue A; Aoki J; Matsuno K; Furuta K; Tanaka S
J Pharmacol Exp Ther; 2024 Mar; 389(1):76-86. PubMed ID: 38290974
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.
Jenkins L; Brea J; Smith NJ; Hudson BD; Reilly G; Bryant NJ; Castro M; Loza MI; Milligan G
Biochem J; 2010 Dec; 432(3):451-9. PubMed ID: 20919992
[TBL] [Abstract][Full Text] [Related]
10. High-throughput identification and characterization of novel, species-selective GPR35 agonists.
Neetoo-Isseljee Z; MacKenzie AE; Southern C; Jerman J; McIver EG; Harries N; Taylor DL; Milligan G
J Pharmacol Exp Ther; 2013 Mar; 344(3):568-78. PubMed ID: 23262279
[TBL] [Abstract][Full Text] [Related]
11. Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats.
Yanni JM; Weimer LK; Glaser RL; Lang LS; Robertson SM; Spellman JM
Int Arch Allergy Immunol; 1993; 101(1):102-6. PubMed ID: 7684628
[TBL] [Abstract][Full Text] [Related]
12. Crucial positively charged residues for ligand activation of the GPR35 receptor.
Zhao P; Lane TR; Gao HG; Hurst DP; Kotsikorou E; Le L; Brailoiu E; Reggio PH; Abood ME
J Biol Chem; 2014 Feb; 289(6):3625-38. PubMed ID: 24347166
[TBL] [Abstract][Full Text] [Related]
13. [In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].
Blondin C; Cholley B; Haeffner-Cavaillon N; Goldschmidt P
J Fr Ophtalmol; 2003 Apr; 26(4):328-36. PubMed ID: 12843888
[TBL] [Abstract][Full Text] [Related]
14. Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35.
Kim MJ; Park SJ; Nam SY; Im DS
Biomol Ther (Seoul); 2020 Jan; 28(1):92-97. PubMed ID: 31189299
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of lodoxamide on eosinophil activation.
Capron M; Loiseau S; Papin JP; Robertson S; Capron A
Int Arch Allergy Immunol; 1998 Jun; 116(2):140-6. PubMed ID: 9652307
[TBL] [Abstract][Full Text] [Related]
16. Antiallergic activity of topical lodoxamide on in vivo and in vitro models.
Ciprandi G; Buscaglia S; Catrullo A; Paolieri F; Riccio AM; Fiorino N; Canonica GW
Allergy; 1996 Dec; 51(12):946-51. PubMed ID: 9020426
[TBL] [Abstract][Full Text] [Related]
17. The characterization of lodoxamide, a very active inhibitor of mediator release, in animal and human models of asthma.
Johnson HG; Sheridan AQ
Agents Actions; 1986 Jun; 18(3-4):301-5. PubMed ID: 2875630
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory gallic Acid and wedelolactone are G protein-coupled receptor-35 agonists.
Deng H; Fang Y
Pharmacology; 2012; 89(3-4):211-9. PubMed ID: 22488351
[TBL] [Abstract][Full Text] [Related]
19. Orthologue selectivity and ligand bias: translating the pharmacology of GPR35.
Milligan G
Trends Pharmacol Sci; 2011 May; 32(5):317-25. PubMed ID: 21392828
[TBL] [Abstract][Full Text] [Related]
20. Hepatic microvascular regulatory mechanisms. V. Effects of lodoxamide tromethamine or phentolamine-HCl on vascular responses elicited by serotonin.
Reilly FD; Cilento EV; McCuskey RS
Microcirc Endothelium Lymphatics; 1984 Dec; 1(6):671-89. PubMed ID: 6100792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
